CL2013000342A1 - Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion. - Google Patents

Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion.

Info

Publication number
CL2013000342A1
CL2013000342A1 CL2013000342A CL2013000342A CL2013000342A1 CL 2013000342 A1 CL2013000342 A1 CL 2013000342A1 CL 2013000342 A CL2013000342 A CL 2013000342A CL 2013000342 A CL2013000342 A CL 2013000342A CL 2013000342 A1 CL2013000342 A1 CL 2013000342A1
Authority
CL
Chile
Prior art keywords
overactive bladder
combinations
treatment
combination
adrenergic beta
Prior art date
Application number
CL2013000342A
Other languages
English (en)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of CL2013000342A1 publication Critical patent/CL2013000342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinaciones de A) Un agonistas del receptor beta-3 adrenérgico y B) Antagonistas del receptor muscarínico para tratar vejiga hiperactiva; un método de tratamiento para la vejiga hiperactiva que comprende la combinación.
CL2013000342A 2010-08-03 2013-02-01 Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion. CL2013000342A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37017110P 2010-08-03 2010-08-03

Publications (1)

Publication Number Publication Date
CL2013000342A1 true CL2013000342A1 (es) 2013-06-28

Family

ID=44511540

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000342A CL2013000342A1 (es) 2010-08-03 2013-02-01 Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion.

Country Status (20)

Country Link
US (1) US8642661B2 (es)
EP (1) EP2600859A1 (es)
JP (2) JP2013535486A (es)
KR (2) KR20130135239A (es)
CN (1) CN103269692B (es)
AP (1) AP2013006742A0 (es)
AR (1) AR084122A1 (es)
AU (1) AU2011285928B9 (es)
BR (1) BR112013002511A2 (es)
CA (1) CA2807135C (es)
CL (1) CL2013000342A1 (es)
CO (1) CO6680685A2 (es)
EA (1) EA030145B1 (es)
MX (1) MX353105B (es)
NZ (1) NZ607485A (es)
PE (1) PE20131341A1 (es)
PH (1) PH12013500221A1 (es)
SG (2) SG187689A1 (es)
TW (1) TW201208667A (es)
WO (1) WO2012018773A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2016004056A1 (en) * 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
EP2891493A4 (en) * 2012-08-31 2016-05-18 Astellas Pharma Inc MEDICAL COMPOSITION ADMINISTERED ORALLY
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
TR201908031T4 (tr) * 2014-08-26 2019-06-21 Astellas Pharma Inc İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu.
CN107205964A (zh) * 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
KR20180069865A (ko) 2015-10-15 2018-06-25 듀크 유니버시티 방광 기능장애를 치료할 수 있는 상태-의존적인 말초 신경제어
US10065922B2 (en) * 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
MX2024010708A (es) 2022-03-02 2024-09-10 Bonafide Health Llc Composiciones de acido poliglutamico y metodos para usarlas.
US12048712B2 (en) * 2022-10-18 2024-07-30 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (es) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6069176A (en) 1995-10-26 2000-05-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as β 3 agonists, process for producing the same, and intermediates in the production of the same
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
WO2005042021A2 (de) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
ES2601503T3 (es) 2005-04-19 2017-02-15 Novartis Ag Composición farmacéutica
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CA2719907A1 (en) 2008-04-04 2009-10-08 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2010129326A1 (en) 2009-05-08 2010-11-11 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
CA2770475C (en) 2009-08-27 2017-06-27 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
AU2010300905B2 (en) 2009-10-02 2016-05-26 Delta T, Llc Air fence for fan blade
IN2012DN02782A (es) * 2009-10-07 2015-09-18 Merck Sharp & Dohme
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
EP2600859A1 (en) 2013-06-12
BR112013002511A2 (pt) 2017-06-27
EA030145B1 (ru) 2018-06-29
AU2011285928A1 (en) 2013-03-07
PE20131341A1 (es) 2013-12-07
PH12013500221A1 (en) 2017-08-23
JP6441267B2 (ja) 2018-12-19
TW201208667A (en) 2012-03-01
AR084122A1 (es) 2013-04-24
WO2012018773A1 (en) 2012-02-09
JP2013535486A (ja) 2013-09-12
CO6680685A2 (es) 2013-05-31
JP2017002074A (ja) 2017-01-05
AU2011285928B9 (en) 2018-08-02
CN103269692A (zh) 2013-08-28
US8642661B2 (en) 2014-02-04
NZ607485A (en) 2015-04-24
MX2013001342A (es) 2013-03-22
AU2011285928B2 (en) 2016-06-16
AP2013006742A0 (en) 2013-02-28
CA2807135C (en) 2019-05-14
CN103269692B (zh) 2018-02-23
EA201390066A1 (ru) 2013-07-30
US20120035118A1 (en) 2012-02-09
MX353105B (es) 2017-12-19
KR20130135239A (ko) 2013-12-10
SG10201506076TA (en) 2015-09-29
CA2807135A1 (en) 2012-02-09
SG187689A1 (en) 2013-03-28
KR20180008918A (ko) 2018-01-24

Similar Documents

Publication Publication Date Title
BR112013002511A2 (pt) combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa
BR112016013963A2 (pt) terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
MX385959B (es) Régimen de dosificación para un agonista de los receptores de s1p.
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
UY33379A (es) Compuestos de morfolina
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder
UY36329A (es) NUEVOS DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
CL2014000991A1 (es) Metodo de tratamiento de una enferemedad autoinmune, que comprende adminsitrar un modulador o agonista del receptor s1p, util en esclerosis multiple; un kit.
BR112016000431A8 (pt) composições e métodos para o tratamento de distúrbios neuropsiquiátricos usando um agonista do receptor de endotelina-b
UY35823A (es) Profármacos de antagonista de nmda
CL2012003201A1 (es) Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.
PH12014500785A1 (en) Method for treating capillary hemangiomas
IL242748B (en) Nmdar agonists for use in the treatment of autoimmune-induced glutamatergic receptor dysfunction
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
AR097287A1 (es) Modulador de los receptores de somatostatina para tratar la infertilidad